.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists recently developed the HSA-C3 anticancer agent. This bimetallic-centered therapeutic increases efficacy while minimizing toxicity. The compound utilizes human serum albumin (HSA) to deliver a bi-copper(II)-centered thiocarbohydrazone directly to tumors. Moreover, C3 integration into an HSA complex improves its pharmacodynamic profile significantly.
Researchers optimized thiocarbohydrazone compounds to create C3, which shows remarkable cytotoxicity. They successfully mapped the HSA-C3 complex. The agent binds specifically to Lys-199 and His-242 residues in the HSA IIA subdomain. Consequently, the HSA-C3 anticancer agent achieves a 74.20% tumor inhibition rate in vivo. In comparison, C3 alone inhibits only 48.71% of growth. Furthermore, this delivery system enhances targeting and reduces adverse side effects.
The HSA-C3 complex also modulates the tumor microenvironment through dual immune activation. Specifically, it blocks the PD-1/PD-L1 interaction to prevent immune evasion. Additionally, the compound resets tumor-associated macrophages toward the M1 phenotype. This approach induces apoptosis and empowers the immune system. Therefore, patients may benefit from more effective and safer metal-based therapies.
The HSA-C3 complex improves outcomes by utilizing human serum albumin as a targeted carrier. This increases the drug concentration at the tumor site. It also boosts the inhibition rate to 74.20%.
The HSA-C3 complex activates the immune system by blocking the PD-1/PD-L1 interaction. It also shifts tumor-associated macrophages to the M1 phenotype, promoting an active immune response.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.
References
Li S et al. Developing a Multitargeted Anticancer Bi-Copper(II)-Centered Thiocarbohydrazone Agent Based on Lys-199 and His-242 Residues in the IIA Subdomain of Human Serum Albumin. J Med Chem. 2026 Mar 24. doi: 10.1021/acs.jmedchem.6c00360. PMID: 41876397.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HSA-C3 complex, a novel bi-copper agent, achieves 74.20% tumor inhibition by targeting human serum albumin and modulating the immune microenvironment....
6 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
